Zeo ScientifiX (ZEOX) removes Chief Science Officer Dr. John Kisiday

Rhea-AI Filing Summary

Zeo ScientifiX, Inc. reported that, effective March 23, 2026, it terminated the employment of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer. This change removes a key scientific executive from the leadership team, and the company has not described any replacement or transition details in this excerpt.

Insights

Corporate governance analyst

Zeo ScientifiX removed its Chief Science Officer, a notable leadership change but with limited disclosed context.

The company states that Dr. John D. Kisiday’s employment as Chief Science Officer was terminated effective March 23, 2026. A Chief Science Officer typically oversees research strategy and scientific programs, so this represents a meaningful change in technical leadership.

The excerpt does not provide reasons for the termination, severance terms, or succession plans, so it is difficult to gauge operational impact. Future disclosures may clarify how Zeo ScientifiX reallocates or replaces scientific leadership responsibilities and whether any strategic R&D priorities are adjusted.

false 0001557376 0001557376 2026-03-23 2026-03-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 23, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective March 23, 2026, the Company terminated the employment of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 27, 2026	ZEO SCIENTIFIX, INC.
	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

2

FAQ

What leadership change did Zeo ScientifiX (ZEOX) disclose in this report?

Zeo ScientifiX disclosed that it terminated the employment of Dr. John D. Kisiday, Ph.D., as its Chief Science Officer, effective March 23, 2026. This removes a key scientific executive from the company’s leadership team, though no replacement or transition plan is outlined in the excerpt.

When did the Chief Science Officer’s termination at Zeo ScientifiX (ZEOX) become effective?

The termination of Dr. John D. Kisiday’s role as Chief Science Officer became effective on March 23, 2026. This effective date marks when he ceased serving in the executive position, as described in the company’s current report under the Securities Exchange Act of 1934.

Does Zeo ScientifiX (ZEOX) explain why the Chief Science Officer was terminated?

The excerpt states that Zeo ScientifiX terminated Dr. John D. Kisiday’s employment as Chief Science Officer, effective March 23, 2026, but does not provide any reasons. No commentary on performance, strategic changes, or personal circumstances is included in the available text of the report.

Who signed the Zeo ScientifiX (ZEOX) report announcing the leadership change?

The report was signed on behalf of Zeo ScientifiX by Ian T. Bothwell, who serves as Chief Executive Officer and Chief Financial Officer. His signature indicates the company’s official authorization of the disclosure under the Securities Exchange Act of 1934.

What role did Dr. John D. Kisiday hold at Zeo ScientifiX (ZEOX) before termination?

Before his termination, Dr. John D. Kisiday, Ph.D., served as Chief Science Officer of Zeo ScientifiX. This role generally involves overseeing the company’s scientific direction and research activities, making his departure a notable change in technical leadership responsibilities.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB